瑞舒伐他汀、辛伐他汀治疗高脂血症伴发冠心病的疗效对比观察

Effect Comparison of Rosuvastatin and Simvastatin in Hyperlipidemia Patients with Coronary Heart Disease

目的观察瑞舒伐他汀、辛伐他汀治疗高脂血症伴发冠心病疗效对比。方法选择2017年5月至2018年5月在我院进行高脂血症伴冠心病治疗的310例患者为研究对象,按照随机数字法分成对照组和观察组,每组各155例。对照组给予辛伐他汀片口服治疗,观察组给予瑞舒伐他汀片口服治疗。对比两组患者治疗前后血脂:三酰甘油、低密度脂蛋白胆固醇及总胆固醇、高密度脂蛋白胆固醇、载脂蛋白B、载脂蛋白A1指标水平;炎性指标:高敏C反应蛋白水平;安全性指标:丙氨酸转氨酶、肌酸磷酸激酶、血尿素氮、血清肌酐水平。结果两组患者治疗前在TG、LDL-C、TC、HDL-C方面水平比较差异无统计学意义(P>0.05),观察组治疗4周、8周后血脂指标水平明显优于对照组,比较组间差异具有统计学意义(P<0.05);两组患者治疗前在Apo B、Apo A1、hs-CRP方面水平比较差异无统计学意义(P>0.05),治疗后两组患者各项指标均有所下降,对照组下降幅度小于观察组,比较组间差异具有统计学意义(P<0.05);两组患者治疗前在ALT、CK、BUN、Cr方面指标比较差异无统计学意义(P>0.05),治疗后观察组各指标均优于对照组,比较组间差异具有统计学意义(P<0.05)。结论瑞舒伐他汀、辛伐他汀均可用于治疗高脂血症伴发冠心病患者,但瑞舒伐他汀疗效优于辛伐他汀,且对肝肾功能影响较小,值得临床推广。

Objective To compare the effect of Rosuvastatin and Simvastatin in hyperlipidemia patients with coronary heart disease(CHD).Methods 310 hyperlipidemia patients with CHD treated from May 2017 to May 2018 in our hospital were selected and randomly assigned to two groups,155 cases in each group.The control group orally took Simvastatin;the observation group orally took Rosuvastatin.The blood lipid indicators including triglyceride(TG),lowdensity lipoprotein cholesterol(LDL-C),total cholesterol(TC),high-density lipoprotein cholesterol(HDL-C),apolipoprotein B(Apo B)and apolipoprotein A1(Apo A1),inflammatory factors including high-sensitivity C-reactive protein(hs-CRP)as well as safety index including alanine aminotransferase(ALT),creatine phosphokinase(CK),blood urea nitrogen(BUN)and serum creatinine(Cr)were compared.Results Before treatment,the values of TG,LDL-C,TC and HDL-C between groups showed no statistically significant difference(P>0.05);after 4 w and 8 w of treatment,blood lipid indicators in the observation group were better than control group(P<0.05);before treatment,the values of Apo B,Apo A1 and hs-CRP between groups showed no statistically significant difference(P>0.05);after treatment,related indicators for two groups were slightly reduced,the descending range in the control group was smaller than observation group(P<0.05);before treatment,the values of ALT,CK,BUN and Cr between groups showed no statistically significant difference(P>0.05);after treatment,related index in the observation group were better than control group(P<0.05).Conclusion Both of Rosuvastatin and Simvastatin is clinically proven to be effective.However,Rosuvastatin has better effects and produces less impact in hepatic and renal function.It is worthy of clinical promotion.